Published in Mol Cancer Res on October 13, 2010
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet (2011) 2.36
Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 1.86
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther (2014) 1.21
New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol (2012) 1.05
Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99
A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget (2014) 0.92
Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling. PLoS One (2013) 0.85
ADAMTS-18: a metalloproteinase with multiple functions. Front Biosci (Landmark Ed) (2014) 0.82
Emerging Roles of ADAMTSs in Angiogenesis and Cancer. Cancers (Basel) (2012) 0.80
ERBB4 mutation analysis: emerging molecular target for melanoma treatment. Methods Mol Biol (2014) 0.78
RNAi screening of the human colorectal cancer genome identifies multifunctional tumor suppressors regulating epithelial cell invasion. Cell Res (2012) 0.77
Identification of a thrombin cleavage site and a short form of ADAMTS-18. Biochem Biophys Res Commun (2012) 0.76
ADAMTS-18 in the host tissues exerts little effect on breast tumor progress in a murine 4T1 breast cancer model. J Negat Results Biomed (2016) 0.75
Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Consed: a graphical tool for sequence finishing. Genome Res (1998) 59.36
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
The ADAMTS metalloproteinases. Biochem J (2005) 3.95
Emerging roles of proteases in tumour suppression. Nat Rev Cancer (2007) 3.81
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
ADAMs in cancer cell proliferation and progression. Cancer Sci (2007) 2.69
Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet (2003) 2.69
Automating resequencing-based detection of insertion-deletion polymorphisms. Nat Genet (2006) 2.61
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res (2008) 2.55
METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem (1999) 2.40
Proteases: multifunctional enzymes in life and disease. J Biol Chem (2008) 2.30
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev (2010) 2.27
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem (2000) 2.11
Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat Biotechnol (2010) 1.98
Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem (2003) 1.87
The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer (2010) 1.80
Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res (2009) 1.72
Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem (2007) 1.66
Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res (2008) 1.57
Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res (1999) 1.55
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie (2007) 1.49
Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J Biol Chem (2002) 1.39
The secreted metalloprotease ADAMTS20 is required for melanoblast survival. PLoS Genet (2008) 1.34
Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr Opin Struct Biol (1995) 1.22
Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene (2007) 1.21
Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol (2002) 1.20
Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J Biol Chem (2000) 1.19
Regulation of cell-substrate adhesion by proteoglycans immobilized on extracellular substrates. J Biol Chem (1989) 1.17
Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem (2007) 1.14
Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain. J Biol Chem (2003) 1.14
The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci (2007) 1.13
Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res (2009) 1.10
Discovery and characterization of a novel, widely expressed metalloprotease, ADAMTS10, and its proteolytic activation. J Biol Chem (2004) 1.08
Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene (2006) 1.05
Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis. Oncogene (2010) 1.02
Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br J Cancer (2006) 1.01
High-resolution melting analysis of ADAMTS18 methylation levels in gastric, colorectal and pancreatic cancers. Med Oncol (2009) 0.92
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 24.40
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
LAGAN and Multi-LAGAN: efficient tools for large-scale multiple alignment of genomic DNA. Genome Res (2003) 23.03
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
International network of cancer genome projects. Nature (2010) 20.35
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Distribution and intensity of constraint in mammalian genomic sequence. Genome Res (2005) 18.85
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Topographical and temporal diversity of the human skin microbiome. Science (2009) 15.96
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Identification and characterization of multi-species conserved sequences. Genome Res (2003) 10.18
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A diversity profile of the human skin microbiota. Genome Res (2008) 7.65
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res (2009) 6.83
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. Genome Res (2010) 5.76
Genome analysis of the platypus reveals unique signatures of evolution. Nature (2008) 5.74
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
MultiPipMaker and supporting tools: Alignments and analysis of multiple genomic DNA sequences. Nucleic Acids Res (2003) 4.97
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Initial sequence and comparative analysis of the cat genome. Genome Res (2007) 4.67
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
Genomic instability in laminopathy-based premature aging. Nat Med (2005) 4.54
An intermediate grade of finished genomic sequence suitable for comparative analyses. Genome Res (2004) 4.38
An initial strategy for the systematic identification of functional elements in the human genome by low-redundancy comparative sequencing. Proc Natl Acad Sci U S A (2005) 4.38
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem (2007) 4.22
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol (2005) 4.10
The genome of the ctenophore Mnemiopsis leidyi and its implications for cell type evolution. Science (2013) 4.07
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
Human and mouse proteases: a comparative genomic approach. Nat Rev Genet (2003) 4.02
Comparative and demographic analysis of orang-utan genomes. Nature (2011) 3.83
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet (2002) 3.78
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature (2014) 3.73
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 3.52
Quantitative estimates of sequence divergence for comparative analyses of mammalian genomes. Genome Res (2003) 3.52